Lilly’s experimental obesity drug shows huge weight-loss results in trial
The Indianapolis-based drugmaker said some trial participants saw a level of weight loss similar to what patients experience after bariatric surgery.
Daniel Bradley
Articles
Lilly spending nearly $4B to acquire three vaccine developers
The Indianapolis drugmaker is purchasing Curevo Inc., LimmaTech Biologics AG and Vaccine Co. Inc. to expand its research and development efforts in infectious disease.
Lilly goes on $21B buying spree to build drug pipeline
Deal after deal, Eli Lilly and Co. is using the fruits of its success from developing blockbuster GLP-1 medicines to prepare for its next chapter and build a bridge over a looming patent cliff.
Elanco’s newest medication enters $1.3B US itchy-dog market
The Indianapolis-based company has announced the phased launch of Befrena, a monoclonal antibody injection for treating canine allergic and atopic dermatitis.
Statewide health care collaboration to put focus on education, research, training
The Crossroads Academic Medical Institute, or CAMI, will connect universities, health systems and clinical training sites.
Leaders hope name for Indiana’s biosciences ecosystem will help state share its story
The name BioHeartland was created to give Indiana “a more cohesive and unified way to share the state’s story with investors, companies, researchers and talent around the world,” officials said.
Riley patient is first in Indiana to receive gene therapy for blood condition
Beta thalassemia major, also known as Cooley’s anemia and transfusion-dependent beta thalassemia, causes the body’s red blood cells to produce less hemoglobin than usual.
Greene County hospital serves Anthem with second breach notice over claim payments
The hospital said the second breach notice is related to additional concerns about Anthem’s claim-payment practices and its failure to apply a contract between the hospital and the insurance company correctly.
Lilly announces $50M contribution to UNICEF USA for children’s health
The Indianapolis-based drugmaker will work to support UNICEF’s efforts to strengthen primary health care systems to prevent, detect and manage noncommunicable diseases in children and adolescents.
Lilly CEO David Ricks keeps eye on future while company celebrates history
The Indianapolis-based drugmaker is marking 150 years since Col. Eli Lilly founded his company on May 10, 1876.
Food partnership, life sciences speaker series unveiled at Lilly’s 150th anniversary event
Former Indianapolis Colts quarterback Peyton Manning emceed the event, which took place before about 500 attendees at the new Lilly Event Center in downtown Indianapolis.
Lilly announces additional $4.5B investment at LEAP District manufacturing site
Lilly’s latest commitment at the LEAP District brings the company’s total investment there since 2022 to $18 billion.
Corteva announces name of new seed and genetics company
In October, Corteva’s board of directors unanimously approved a plan to separate the company’s crop protection business and its seed business into two independent companies.
2026 Innovation Issue: Beck’s Hybrids AI platform educates farmers about their crops
In February, Beck’s publicly launched SeedIQ, a free online product management platform that uses artificial intelligence to provide data and management recommendations to help farmers unlock the potential of their corn and soybean hybrids.
2026 Innovation Issue: With coding academies gone, what comes next?
In Indiana, gone are Eleven Fifty Academy and Kenzie Academy. National coding bootcamps like Bloom Institute of Technology, Hack Reactor and Triology have significantly scaled back or totally restructured in recent years.
Lilly earnings increase as Mounjaro, Zepbound sales continue rise
The Indianapolis-based drugmaker reported profit of $7.4 billion for the first quarter, up from $2.8 billion in the same period a year earlier.
Lilly signs $2.25B deal with California-based AI firm to develop genetic medicine
The Indianapolis-based drugmaker will partner with Profluent to develop and commercialize treatments for diseases with severe unmet needs.
Lilly acquiring cancer-drug firm Ajax Therapeutics in deal worth up to $2.3B
The acquisition is the latest in a series of recent deals that Indianapolis-based Eli Lilly and Co. has made to increase its cancer-treatment pipeline.
Complex process leads to a new drug’s identity
The laborious process of naming a pharmaceutical takes months and sometimes years of brainstorming, trademark review, legal analysis and regulatory compliance.
Central Indiana excelling in life sciences, but it needs a brand, speakers say
The region stands out for its prowess in invention and innovation, but competing markets have mastered telling their stories, according to speakers at IBJ’s Life Sciences Power Breakfast.